MFH yields 35.40% · JNJ yields 2.13%● Live data
📍 MFH pulled ahead of the other in Year 1
Combined, MFH + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MFH + JNJ for your $10,000?
Mercurity Fintech Holding Inc. engages in the design, development, creation, testing, installation, configuration, integration, and customization of operational software based on blockchain technologies and related services in the British Virgin Islands and the Asia pacific region. It provides digital asset trading infrastructure solutions based on internet and blockchain technologies for cryptocurrency traders, blockchain-based virtual communities, and liquidity providers.; an asset digitalization platform, which provides blockchain-based digitalization solutions for traditional assets, such as fiat currencies, bonds, and precious metals. The company also offers a decentralized finance platform that solves retail traders' problems; cross-border payments services; and supplemental services for its platforms, such as customized software development, maintenance, and compliance support services. In addition, it provides blockchain technology services, which includes designing and developing digital asset transaction platforms, digital asset quantitative investment software, and other innovative and derivative services based on blockchain technologies; and cryptocurrency mining services that provides computing power to the mining pool. The company was formerly known as JMU Limited and changed its name to Mercurity Fintech Holding Inc. in April 2020. Mercurity Fintech Holding Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.
Full MFH Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.